PDF   Print   View All
April 22, 2003
HEMISPHERX BIOPHARMA EXTENDS DISTRIBUTOR AGREEMENT FOR ALFERON N Injection
National Institute of Health reports 5.5 Million new genital Human Pamplona Virus outbreaks each year
Center of Disease Control reports related Sexually Transmitted Diseases healthcare costs second only to HIV



Philadelphia, PA, Tuesday, April 22, 2003: announced today that it has expanded its Agreement with Integrated Commercial Systems (ICS) for the distribution of Alferon N Injection in North America. The Agreement provides a custom-made program to market the drug and a cost effective commercial infrastructure.

ICS provides a simple, single-source solution to the complex challenges of taking new health care products to market. Under the Agreement with Hemispherx, ICS provides distribution and clinical support services, including placement of orders, order management, warehousing and shipping, invoicing, reporting, accounts receivable activity and others. For more information on ICS visit their website at www.icsconnect.com.

The growing market for Alferon N in the U.S.

Hemispherx lead product, Alferon N Injection, a natural form of human leukocyte derived Interferon, is currently approved by the FDA for the intralesional treatment of refractory or recurring condylomata HPV in adult patients. According to the National Institute of Allergy and Infectious Diseases Fact Sheet there are approximately 5.5 million new genital HPV infections each year with more than 20 million people in the United States currently infected. Healthcare costs associated with sexually transmitted diseases (STD) caused by HPV rank second only to those associated with sexually transmitted diseases caused by human immunodeficiency virus (HIV) according to the U.S. Department of Health and Human Services Centers for Disease Control and Prevention.

Contact information for Health Care Professionals

To learn more about potential treatment, physicians and patients should contact our ALFERON ACCESS PROGRAM by phone at 1-888-ALFERON or by fax at 1-888-FAXX AFN for more information or visit our updated website www.hemispherx.net under the newly launched Product Section. Health Care Professionals interested in clinical trials should contact the Medical Director at Hemispherx.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon®, Ampligen® and Oragens™. These novel proteins and nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net, it provides compassionate programs to qualifying patients for both Ampligen® and Alferon®.


Contact(s):
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Robert Giordano, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon do not imply that the product will be specifically approved commercially for these other treatment indications.